Hello !
Do anybody know a clinical study where number of Covid19 cases has been compared between hypertensive patients taking renine-angiotensine system inhibitors with the one that are under bblockers / or Calcium channel inhibitors ?
All the answers on this amazing website ! : http://www.nephjc.com/news/covidace2
No study to is available to date. A retrospective case control study is immediately possible, if one notes the severity and mortality of illness in patients with COVID-19 with 3 groups:
- Patients without hypertension (as control group),
- Patients with hypertension on ACE inhibitors or ARBs
- Patients with hypertension on Calcium channel blockers
In this pandemic situation of COVID-19, forget about a prospective double blind or even single blind study.
Article COVID‐19: Social distancing, ACE 2 receptors, protease inhib...
You have probably already seen this, no clinical study!
I would personally prefer switching from ACE / ARB to an alphablocker in hypertensive men admitted to hospital. Whilst alphablockers do cause slightly more postural hypertension. Their effect on reduction of prostatic hypertrophy is beneficial particularly for improving the success rate of removal of Foley catheters.
Covid-19 is more severe in men than in women. Unwell patients often require urethral catheterisation so this effect of alphablockade may be beneficial.
No harmful effects of RAAS inhibitors in COVID-19 patients
Recent data has not shown any detrimental effects of using ACE inhibitors or ARBs when indicated in patients with COVID-19. No need to switch to alternative antihypertensive or heart failure medications (1-3).
1. Article Renin-Angiotensin System Inhibitors and COVID-19: Potential ...
2.Article COVID‐19 and Renin‐Angiotensin system inhibition – role of a...
3. Article Association of Renin-Angiotensin System Inhibitors With Seve...